| Identification | Back Directory | [Name]
2-Pyridinecarboxamide, N-[6-[(3R,6R)-5-amino-3,6-dihydro-3,6-dimethyl-6-(trifluoromethyl)-2H-1,4-oxazin-3-yl]-5-fluoro-2-pyridinyl]-3-chloro-5-(trifluoromethyl)-, hydrochloride (1:1) | [CAS]
2365306-62-1 | [Synonyms]
Umibecestat HCl
2-Pyridinecarboxamide, N-[6-[(3R,6R)-5-amino-3,6-dihydro-3,6-dimethyl-6-(trifluoromethyl)-2H-1,4-oxazin-3-yl]-5-fluoro-2-pyridinyl]-3-chloro-5-(trifluoromethyl)-, hydrochloride (1:1) | [Molecular Formula]
C19H16Cl2F7N5O2 | [MOL File]
2365306-62-1.mol | [Molecular Weight]
550.26 |
| Hazard Information | Back Directory | [Description]
Umibecestat, also known as CNP-520, is a beta-secretase inhibitor and is a drug candidate for prevention trials in Alzheimer's disease. CNP520 has a selectivity, pharmacodynamics, and distribution profile suitable for AD prevention studies. CNP520 reduced brain and cerebrospinal fluid (CSF) Aβ in rats and dogs, and Aβ plaque deposition in APP-transgenic mice. CNP520 reduces Aβ load and neuroinflammation in APP‐transgenic mice |
|
|